according to Joshua D. Safer, MD, executive director of the Mount Sinai Center for Transgender Medicine and Surgery, New York.
“It’s not that we have to be the experts on making diagnoses or other elements of transgender care, necessarily,” Dr. Safer said in an interview here at the annual scientific & clinical congress of the American Association of Clinical Endocrinologists.
In a meet-the-expert session at AACE,talked about the “change in landscape” in transgender medical care that precipitated the Endocrine Society on endocrine treatment of gender-dysphoric/gender-incongruent individuals.
The new guidelines, published just this past fall, updated guidance published by the society back in 2009.
One big change for pediatrics in the new guidelines is the recognition that there may be “compelling reasons” to start cross-sex hormonal therapy prior to 16 years, the former age cut-off. Sixteen years is “very late if you’re thinking about it from a biological perspective,” said Dr. Safer, who was a coauthor of the new guidelines.
While there are only limited data on using gender-affirming hormones in younger adolescents, there are potential risks of waiting until age 16 years in some cases, according to the guidelines.